The MARIPOSA trials — implications for the treatment of EGFR-mutant NSCLC

In the past 2 years, substantial improvements have been made in the management of advanced-stage EGFR -mutant non-small-cell lung cancer. Recent studies have suggested added benefit from the combination of third-generation tyrosine-kinase inhibitors with either chemotherapy or a bispecific antibody targeting EGFR and MET. Herein, we summarize these advances and their implications for clinical practice.